drugset / Trial / NCT02773225
Efficacy and Safety of Eltrombopag + CSA in Patients With Moderate Aplastic Anemia (EMAA)
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The aim of this study is to improve treatment of Moderate Aplastic Anemia (MAA) by evaluating the safety and efficiency of Eltrombopag as a new treatment option in patients with therapy requiring MAA.
Timeline
- Start
- 2015-01-27
- Primary completion
- 2025-01-30
- Completion
- 2025-01-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Eltrombopag | Small molecule | 75 mg | Oral |
| Subject | Eltrombopag | Small molecule | 150 mg | Oral |